A groundbreaking discovery in the fight against tuberculosis (TB) has the potential to revolutionize treatment. An international collaboration has unveiled promising results from a trial of a novel antibiotic, offering hope for a shorter and simpler treatment journey for TB patients.
The phase 2 trial data, presented at the Union World Conference on Lung Health in Copenhagen, revealed that sorfequiline (TBAJ-876) demonstrated superior activity against drug-susceptible TB compared to existing treatments after 8 weeks, with an encouraging safety profile. This second-generation diarylquinoline antibiotic is a game-changer, and the trial marks its first human testing.
Dr. Maria Beumont, a key investigator from TB Alliance, emphasized the significance of these results, stating they provide a strong foundation to progress to phase 3 trials. She believes sorfequiline has the potential to reduce treatment durations for both drug-susceptible and drug-resistant TB, impacting the lives of millions.
"We envision a future where TB treatment is incredibly brief, and this trial is the initial step towards that goal," she shared with CIDRAP News.
The randomized controlled trial, conducted across South Africa, the Philippines, Georgia, Tanzania, and Uganda, involved 309 participants newly diagnosed with drug-susceptible TB. Participants were divided into five treatment groups: HRZE (standard first-line regimen), BPaL (recommended for drug-resistant TB), and SPaL (sorfequiline-based regimen) with three different sorfequiline doses (25, 50, and 100 mg). The primary focus was on sputum conversion, a critical measure of treatment efficacy, at week 8.
At week 8, the results were remarkable. The proportion of participants with sputum conversion was 59% in the SPaL group receiving 100 mg of sorfequiline, compared to 45% in both the HRZE and BPaL groups. This indicates a more effective and robust treatment, as Dr. Beumont explained: "It's bringing down the Mycobacterium burden faster, which is a strong indicator of efficacy and the potential to reduce treatment duration."
The safety profile of SPaL was comparable to HRZE, and participants responded positively to the simpler three-pill regimen. Thuto Pulane, a trial participant, shared their experience: "The treatment was incredible. It was shorter and easier than I anticipated."
TB Alliance plans to initiate a phase 3 trial, testing SPaL in both drug-susceptible and drug-resistant TB patients. If successful, Dr. Beumont envisions a 4-month treatment duration, with just one month of oral pills followed by a long-lasting injectable form, ensuring complete eradication of the disease.
"From the patient's perspective, it's just one month of pills," she added.
There's also the potential for SPaL to become a universal initial treatment for all TB-positive patients, eliminating the wait for test results to determine drug susceptibility. In resource-limited settings, this could significantly improve treatment outcomes and patient experiences.
Dr. KJ Seung, a TB researcher not involved in the trial, highlighted the importance of these interim results, stating: "It's encouraging to see new TB drugs in the pipeline, especially given the rise of drug resistance."
This breakthrough offers a glimmer of hope in the ongoing battle against TB, and the potential for a shorter, more effective treatment is a step towards a healthier future for millions.
